Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-05-06
2008-05-06
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S267000, C544S251000
Reexamination Certificate
active
07368449
ABSTRACT:
Compounds having the structural formula Ior a pharmaceutically acceptable salt thereof, whereinR isR1, R2, R3, R4and R5are H, alkyl or alkoxyalkyl;R6is H, alkyl, hydroxyalkyl or —CH2F;R7, R8and R9are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF3; andZ is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed.Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.
REFERENCES:
patent: 5565460 (1996-10-01), Suzuki et al.
patent: 6897217 (2005-05-01), Neustadt et al.
patent: 2002/0099061 (2002-07-01), Neustadt et al.
patent: 2004/0138235 (2004-07-01), Grezlak et al.
patent: WO 95/01356 (1995-01-01), None
patent: WO 97/05138 (1997-02-01), None
patent: WO98/52568 (1998-11-01), None
patent: WO 01/92264 (2001-12-01), None
patent: WO 02/055083 (2002-07-01), None
patent: WO 03/032996 (2003-04-01), None
Merck, Parkinson's Disease (Jun. 25, 2007), 5 pages.
Merck, Introduction: Movement and Cerebellar Disorders (Jun. 25, 2007), 2 pages.
Baraldi et al,J. Med. Chem., 39 (1996), 1164-1171.
Huang et al,Tet. Lett., 40 (1999), 8647-8650.
Varelis et al,Aust. J. Chem., 48 (1995), 1775-1779.
Kanth et al,J. Org. Chem., 56 (1991), 5964-5965.
Orito et al,Synthesis, 23 (1997), 23-25.
Aiba et al,Bioorg. Med. Chem. Lett., 11 (2001), 2783-2786.
Baum et al,J. Org. Chem., 48 (1983), 2953-2956.
Cornelius et al,Synth. Comm., 24, (19) (1994), 2777-2788.
Lee et al,Synth. Comm., 33, (9) (2003),1611-1614.
Ungerstedt et al,Brain Research, 24 (1970), 485-493.
Ungerstedt,Eur. J. Pharmacol., 5 (1968), 107-110.
Baraldi et al,J. Med. Chem., 43 (2000) 4768-80.
Baraldi et al,Bioorganic and Med. Chem. Let., 4 (21) (1994) 2539-44.
Ongini et al,PubMed Abstract(Ann. N Y Acad. Sci. 825:30-48), Oct. 1997.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20thEd., vol. 2, p. 2050-2057, 1996.
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thEd., vol. 2, p. 1992-1996, 1996.
Merck, Periodic Limb Movement Disorder and Rest Syndrome (RLS) (Apr. 10, 2007), 2 pages.
Trenkwalder et al., The Restless Legs Syndrome, Neurology, vol. 4: 465-475 (Aug. 2005).
Rao et al., Parkinson's Disease: Diagnosis and Treatment, American Family Physician, vol. 74:12, 2046-2054 (Dec. 2006).
Berkow et al., Fifteenth Edition The Merck Manual of Diagnosis and Therapy, 2 pages (1987).
Weiden, P.J., EPS Profiles: the atypical antipsychotics are not all the same (Apr. 9, 2007)—2 pages.
Boyle Craig D.
Chackalamannil Samuel
Hao Jinsong
Liu Hong
Neustadt Bernard R.
Banerjee Krishna G.
Rao Deepak
Schering Corporation
LandOfFree
2-alkynyl- and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-alkynyl- and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-alkynyl- and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2782608